Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution and Dosimetry of [68Ga]/ [131I]-IR199 in Gastric and Pancreatic Cancer
NCT07707531Phase 1Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IR199 in gastric cancer (GC) and pancreatic cancer (PC), sponsored by Huashan Hospital. Primary endpoint: Absorbed radiation dose distribution in normal organs and tumors at 72 hours. Started Jun 2026; status: recruiting.
02
Drugs
IR199
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07707531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707531.